Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19

Monique G.p. van der Wijst, Sara E. Vazquez, George C. Hartoularos, Paul Bastard, Tianna Grant, Raymund Bueno, David Lee, John R. Greenland, Yang Sun, Richard K. Perez, Anton Ogorodnikov, Alyssa Ward, Sabrina A Mann, Kara L. Lynch, Cassandra Yun, Diane V. Havlir, Gabriel Chamie, Carina Marquez, Bryan Greenhouse, Michail S. Lionakis, Philip J. Norris, Larry J. Dumont, Kathleen Kelly, Peng Zhang, Qian Zhang, Adrian Gervais, Tom Le Voyer, Alexander Whatley, Yichen Si, Ashley Byrne, Alexis J. Combes, Arjun A. Rao, Yun S. Song, Gabriela K. Fragiadakis, Kirsten N. Kangelaris, Carolyn S. Calfee, David J. Erle, Carolyn M. Hendrickson, Matthew F. Krummel, Prescott G. Woodruff, Charles Langelier, Jean‐Laurent Casanova, Joseph L. DeRisi, Mark S. Anderson, Chun YebioRxiv 2021 · DOI

Abstract

Type I interferon (IFN-I) neutralizing autoantibodies have been found in some critical COVID-19 patients; however, their prevalence and longitudinal dynamics across the disease severity scale, and functional effects on circulating leukocytes remain unknown. Here, in 284 COVID-19 patients, we found IFN-I autoantibodies in 19% of critical, 6% of severe and none of the moderate cases. Longitudinal profiling of over 600,000 peripheral blood mononuclear cells using multiplexed single-cell epitope and transcriptome sequencing from 54 COVID-19 patients, 15 non-COVID-19 patients and 11 non-hospitalized healthy controls, revealed a lack of IFN-I stimulated gene (ISG-I) response in myeloid cells from critical cases, including those producing anti-IFN-I autoantibodies. Moreover, surface protein analysis showed an inverse correlation of the inhibitory receptor LAIR-1 with ISG-I expression response early in the disease course. This aberrant ISG-I response in critical patients with and without IFN-I autoantibodies, supports a unifying model for disease pathogenesis involving ISG-I suppression via convergent mechanisms.

Introduction

One of the most enduring mysteries of the COVID-19 pandemic is clinical heterogeneity: why does one person experience a mild cough while another, of similar age and health, ends up on a ventilator? Recent studies have pointed toward "inborn errors" of immunity, specifically involving Type I Interferons (IFN-I)—the body’s first-line antiviral defense. This paper investigates a specific subset of this problem: autoantibodies that neutralize the patient's own interferon proteins. While these antibodies were known to exist, their longitudinal evolution and specific impact on individual immune cell behavior remained poorly understood.

Methods

The researchers employed a high-resolution approach called muxCITE-seq (multiplexed single-cell epitope and transcriptome sequencing). This allowed for the simultaneous measurement of transcriptomics (mRNA) and proteomics (189 cell-surface markers) in over 600,000 individual cells. To track the immune system's progression, samples were collected longitudinally at days 0, 4, 7, and 14 of hospitalization.

To establish prevalence, the study integrated data from multiple sources:

  • SFGH Cohort: 284 COVID-positive subjects to map autoantibodies across the severity scale.
  • COMET Cohort: 69 hospitalized patients and 11 healthy controls for deep single-cell profiling.
  • Community Cohort: 4,041 subjects from San Francisco to determine "baseline" prevalence in the general population.
  • Convalescent Plasma: 175 unique donors to ensure these antibodies aren't transferred via plasma therapy.

Key Results

Prevalence and Pre-existing Vulnerability

Autoantibodies to IFN-α2 were found in 19% of critical cases and 6% of severe cases, but were entirely absent in moderate disease. Because these antibodies were found at high levels at the moment of hospitalization and were also present in a small percentage of the healthy community (0.32%), evidence suggests they pre-date infection. They act as a pre-existing "trap door" to critical illness rather than a result of the infection itself.

The "Unifying Model" of Severity

A striking finding was that critical patients—both those with and without detectable autoantibodies—showed a similarly deficient Interferon-Stimulated Gene (ISG) response in their myeloid cells (monocytes and dendritic cells). This suggests that critical COVID-19 may be defined by a convergent failure of the interferon system, with autoantibodies being one major trigger.

LAIR-1 as a Negative Sentinel

Surface protein analysis identified LAIR-1, an inhibitory receptor on classical monocytes, as a specific biomarker. Its expression was inversely correlated with the interferon response (Pearson R = -0.47). High LAIR-1 levels early in the disease course appear to act as a "brake" on the immune system, predicting a poor clinical outcome.

Discussion and Future Directions

While autoantibodies explain approximately 20% of critical cases, the convergent mechanism for the remaining 80% remains partially obscured. Future work is needed to determine if these patients have "hidden" autoantibodies or different genetic defects. Furthermore, the study suggests that IFN-β (which is less targeted by these specific autoantibodies) might be a viable therapeutic strategy for this high-risk group. The identification of LAIR-1 provides a potential tool for early risk stratification in clinical settings.

Summary updated

Abstract

Type I interferon (IFN-I) neutralizing autoantibodies have been found in some critical COVID-19 patients; however, their prevalence and longitudinal dynamics across the disease severity scale, and functional effects on circulating leukocytes remain unknown. Here, in 284 COVID-19 patients, we found IFN-I autoantibodies in 19% of critical, 6% of severe and none of the moderate cases. Longitudinal profiling of over 600,000 peripheral blood mononuclear cells using multiplexed single-cell epitope and transcriptome sequencing from 54 COVID-19 patients, 15 non-COVID-19 patients and 11 non-hospitalized healthy controls, revealed a lack of IFN-I stimulated gene (ISG-I) response in myeloid cells from critical cases, including those producing anti-IFN-I autoantibodies. Moreover, surface protein analysis showed an inverse correlation of the inhibitory receptor LAIR-1 with ISG-I expression response early in the disease course. This aberrant ISG-I response in critical patients with and without IFN-I autoantibodies, supports a unifying model for disease pathogenesis involving ISG-I suppression via convergent mechanisms.
BibTeX
@misc{wijst2021longitudinal,
  author = {Monique G.P. van der Wijst and Sara E. Vazquez and George C. Hartoularos and Paul Bastard and Tianna Grant and Raymund Bueno and David Lee and John R. Greenland and Yang Sun and Richard K. Perez and Anton Ogorodnikov and Alyssa Ward and Sabrina A Mann and Kara L. Lynch and Cassandra Yun and Diane V. Havlir and Gabriel Chamie and Carina Marquez and Bryan Greenhouse and Michail S. Lionakis and Philip J. Norris and Larry J. Dumont and Kathleen Kelly and Peng Zhang and Qian Zhang and Adrian Gervais and Tom Le Voyer and Alexander Whatley and Yichen Si and Ashley Byrne and Alexis J. Combes and Arjun A. Rao and Yun S. Song and Gabriela K. Fragiadakis and Kirsten N. Kangelaris and Carolyn S. Calfee and David J. Erle and Carolyn M. Hendrickson and Matthew F. Krummel and Prescott G. Woodruff and Charles Langelier and Jean‐Laurent Casanova and Joseph L. DeRisi and Mark S. Anderson and Chun Ye},
  title = {{Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19}},
  year = {2021},
  doi = {10.1101/2021.03.09.434529},
  howpublished = {bioRxiv},
}
Figure